Silk Road Medical Inc. is a medical device company that focuses on developing innovative treatments for patients with vascular conditions. The company was founded in 2007 by Dr. Tony Chou, a vascular surgeon, and Erica Rogers, a medical device executive. It is based in Sunnyvale, California, USA. Silk Road Medical Inc. is listed on the NASDAQ stock exchange under the ticker symbol "SILK."
Silk Road Medical is dedicated to addressing the unmet needs in treating complex vascular conditions, particularly those involving the carotid artery. The carotid artery is a major blood vessel in the neck that supplies oxygenated blood to the brain. Blockages or narrowing in this artery can lead to serious medical conditions, such as strokes.
The company's flagship product is the Enroute Transcarotid Neuroprotection System (NPS), which is designed to treat carotid artery disease. The NPS allows for a minimally invasive procedure called Transcarotid Artery Revascularization (TCAR), which helps in reducing the risk of stroke during the treatment.
The company has made significant advancements in the field of vascular interventions, providing physicians with novel tools and techniques to improve patient outcomes. With a mission to transform the treatment of carotid artery disease, Silk Road Medical continues to focus on research, development, and innovation in the medical device space. Its products are used by vascular specialists worldwide to improve the quality of care for patients with complex vascular conditions.